Evidence map›Paper›PMID 36712613›Full record

ArticleRSC advances2023

Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins.

Takuya Kobayakawa, Masaru Yokoyama, Kohei Tsuji, Masayuki Fujino, Masaki Kurakami, Takato Onishi, Sayaka Boku, Takahiro Ishii, Yutaro Miura, Kouki Shinohara and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Takuya KobayakawaInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.ORCID https://orcid.org/0000-0001-9786-2608
Masaru YokoyamaPathogen Genomics Center, National Institute of Infectious Diseases Musashimurayama 208-0011 Tokyo Japan hirosato@nih.go.jp.
Kohei TsujiInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.ORCID https://orcid.org/0000-0003-4773-8793
Masayuki FujinoAIDS Research Center, National Institute of Infectious Diseases Shinjuku-ku Tokyo 162-8640 Japan tmura@nih.go.jp.
Masaki KurakamiInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.
Takato OnishiInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.
Sayaka BokuInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.
Takahiro IshiiInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.
Yutaro MiuraInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.
Kouki ShinoharaInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.
Yuki KishiharaInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.
Nami OhashiShowa Pharmaceutical University Machida 194-8543 Tokyo Japan.
Osamu KotaniPathogen Genomics Center, National Institute of Infectious Diseases Musashimurayama 208-0011 Tokyo Japan hirosato@nih.go.jp.
Tsutomu MurakamiAIDS Research Center, National Institute of Infectious Diseases Shinjuku-ku Tokyo 162-8640 Japan tmura@nih.go.jp.
Hironori SatoPathogen Genomics Center, National Institute of Infectious Diseases Musashimurayama 208-0011 Tokyo Japan hirosato@nih.go.jp.
Hirokazu TamamuraInstitute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU) 2-3-10 Kandasurugadai, Chiyoda-ku Tokyo 101-0062 Japan tamamura.mr@tmd.ac.jp.ORCID https://orcid.org/0000-0003-2788-2579
Tokyo Medical and Dental University · JPNational Institute of Infectious Diseases · JPShowa Pharmaceutical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The HIV-1 capsid is a shell that encapsulates viral RNA, and forms a conical structure by assembling oligomers of capsid (CA) proteins. Since the CA proteins are highly conserved among many strains of HIV-1, the inhibition of the CA function could be an appropriate goal for suppression of HIV-1 replication, but to date, no drug targeting CA has been developed. Hydrophobic interactions between two CA molecules through Trp184 and Met185 in the protein are known to be indispensable for conformational stabilization of the CA multimer. In our previous study, a small molecule designed by

Identifiers

PMID36712613
PMCPMC9834766
OpenAlexW4315781855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.